Horst Lindhofer Selected Research

9-O-acetyl-GD3 ganglioside

11/2012

Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Horst Lindhofer Research Topics

Disease

33	Neoplasms (Cancer) 10/2021 - 02/2002
12	Ascites 06/2014 - 11/2005
7	Melanoma (Melanoma, Malignant) 01/2017 - 02/2004
5	Ovarian Neoplasms (Ovarian Cancer) 07/2014 - 07/2007
4	Peritoneal Neoplasms 01/2018 - 11/2005
3	Nausea 01/2018 - 05/2006
3	Carcinoma (Carcinomatosis) 01/2012 - 05/2010
3	Fever (Fevers) 01/2011 - 05/2006
2	Stomach Neoplasms (Stomach Cancer) 01/2018 - 11/2010
2	Abdominal Pain (Pain, Abdominal) 01/2018 - 01/2011
2	Vomiting 01/2011 - 05/2006
2	Lymphoma (Lymphomas) 05/2010 - 02/2002
2	Breast Neoplasms (Breast Cancer) 05/2009 - 05/2006
2	Residual Neoplasm 08/2008 - 02/2006
2	Graft vs Host Disease (Graft-Versus-Host Disease) 08/2008 - 02/2006
1	Non-Muscle Invasive Bladder Neoplasms 09/2021
1	Neuroblastoma 01/2021
1	Infections 01/2018
1	Ovarian Epithelial Carcinoma 07/2014
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2011
1	Malignant Pleural Effusion 02/2009
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2007
1	Body Weight (Weight, Body) 01/2007
1	Lymphopenia (Lymphocytopenia) 05/2006
1	Headache (Headaches) 05/2006
1	Experimental Melanoma 02/2006
1	Neoplasm Micrometastasis 11/2005
1	B-Cell Lymphoma (Lymphoma, B Cell) 02/2002

Drug/Important Bio-Agent (IBA)

17	Epithelial Cell Adhesion MoleculeIBA 10/2021 - 11/2005
16	catumaxomabIBA 10/2021 - 07/2007
11	AntibodiesIBA 01/2021 - 02/2004
10	AntigensIBA 01/2021 - 02/2002
9	Bispecific AntibodiesIBA 01/2017 - 11/2005
4	Immunoglobulin G (IgG)IBA 01/2021 - 05/2010
4	CytokinesIBA 01/2021 - 02/2004
3	Immunoglobulin Fc FragmentsIBA 01/2021 - 08/2012
3	EnzymesIBA 01/2018 - 05/2006
3	GangliosidesIBA 11/2012 - 02/2004
3	ertumaxomabIBA 05/2010 - 05/2006
2	GD2 gangliosideIBA 08/2015 - 08/2012
2	Immunoglobulins (Immunoglobulin)IBA 01/2012 - 02/2009
2	Monoclonal AntibodiesIBA 02/2009 - 10/2007
1	Cytostatic AgentsIBA 09/2021
1	Surface Antigens (Surface Antigen)IBA 01/2021
1	dinutuximabIBA 01/2021
1	Immune Checkpoint InhibitorsIBA 01/2017
1	IpilimumabIBA 01/2017
1	PlatinumIBA 07/2014
1	Biomarkers (Surrogate Marker)IBA 06/2014
1	ParaffinIBA 06/2013
1	AvidinIBA 06/2013
1	Biotin (Vitamin H)FDA Link 06/2013
1	9-O-acetyl-GD3 gangliosideIBA 11/2012
1	InterferonsIBA 08/2012
1	Peptides (Polypeptides)IBA 08/2012
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2012
1	CD3 ComplexIBA 10/2010
1	Hepatitis B e AntigensIBA 05/2010
1	Trastuzumab (Herceptin)FDA Link 05/2009
1	human ERBB2 proteinIBA 05/2009
1	InterleukinsIBA 08/2008
1	Sodium Chloride FDA LinkGeneric 01/2007
1	Pharmaceutical PreparationsIBA 05/2006
1	Immunologic Adjuvants (Immunologic Adjuvant)IBA 11/2005
1	Prednisolone (Predate)FDA LinkGeneric 11/2005
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2005
1	PerforinIBA 02/2004
1	Proteoglycans (Proteoglycan)IBA 02/2004
1	Neoplasm Antigens (Tumor Antigens)IBA 02/2002

Therapy/Procedure

14	Therapeutics 09/2021 - 02/2002
10	Immunotherapy 08/2015 - 11/2005
3	Drug Therapy (Chemotherapy) 07/2014 - 02/2009
2	Aftercare (After-Treatment) 01/2012 - 02/2009
1	Intravesical Administration 09/2021
1	Intravenous Administration 08/2015